Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Influencing Factors01:20

Modified-Release Drug Delivery Systems: Influencing Factors

Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Modified-Release Drug Delivery Systems: Drug Release Characteristics01:22

Modified-Release Drug Delivery Systems: Drug Release Characteristics

Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Traditional Lecture versus Case-Based Learning in a Therapeutic Drug Monitoring Course within an Integrated Pharmacy Curriculum.

Innovations in pharmacy·2022
Same author

Enhanced S-Cone Syndrome: Spectrum of Clinical, Imaging, Electrophysiologic, and Genetic Findings in a Retrospective Case Series of 56 Patients.

Ophthalmology. Retina·2020
Same author

Effect of formulation pH on transdermal penetration of antiemetics formulated in poloxamer lecithin organogel.

International journal of pharmaceutical compounding·2013
Same author

Projected growth in pharmacy education and research, 2010 to 2015.

American journal of pharmaceutical education·2011
Same author

Pharmacy faculty workplace issues: findings from the 2009-2010 COD-COF Joint Task Force on Faculty Workforce.

American journal of pharmaceutical education·2011
Same author

Using the humanities to strengthen the concept of professionalism among first-professional year pharmacy students.

American journal of pharmaceutical education·2007
Same journal

Compounding and Stability Study of Dipyridamole and Clopidogrel Pediatric Oral Suspensions.

International journal of pharmaceutical compounding·2026
Same journal

Nanoemulsion Reformulation of Nitrosylcobalamin (NO-Cbl) Enhances Solubility, Stability, and Anti-Tumor Potency.

International journal of pharmaceutical compounding·2026
Same journal

Chemical and Microbiological Stability Supporting Extended BUDs in Pentravan® Based Transdermal Preparations.

International journal of pharmaceutical compounding·2026
Same journal

Stability Evaluation of Compounded Benzocaine, Lidocaine, and Tetracaine in VersaPro™ Cream Base.

International journal of pharmaceutical compounding·2026
Same journal

Formulation and In-Vitro Characterization of Gastroretentive Effervescent Floating Tablets of Meloxicam.

International journal of pharmaceutical compounding·2026
Same journal

Ethical and Regulatory Implications of Sourcing Drug X During an FDA-Reported Shortage: 503A vs. 503B Compounding Facilities.

International journal of pharmaceutical compounding·2026
See all related articles

Related Experiment Video

Updated: May 8, 2026

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

Isoniazid release from suppositories compounded with selected bases.

Kristofer C Hudson1, C Scott Asbill, Andrew A Webster

  • 1McWhorter School of Pharmacy, Samford University, Birmingham, Alabama.

International Journal of Pharmaceutical Compounding
|August 24, 2013
PubMed
Summary
This summary is machine-generated.

This study explored isoniazid suppository formulations for pediatric tuberculosis. Polyethylene glycol bases showed superior isoniazid release compared to lipophilic bases, offering a promising alternative drug delivery route.

Related Experiment Videos

Last Updated: May 8, 2026

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

Area of Science:

  • Pharmaceutical Sciences
  • Pediatric Pharmacology
  • Drug Delivery Systems

Background:

  • Tuberculosis (TB) treatment in children necessitates alternative administration routes for isoniazid.
  • Optimizing isoniazid suppository formulations is crucial for effective pediatric prophylaxis and treatment.

Purpose of the Study:

  • To evaluate in vitro isoniazid release from extemporaneously compounded suppositories.
  • To compare drug release profiles across different suppository base formulations.

Main Methods:

  • Compounding of isoniazid suppositories using cocoa butter, Witepsol H15, and polyethylene glycol bases.
  • In vitro drug release testing using a USP-approved dissolution apparatus.
  • Quantification of isoniazid concentrations via high-performance liquid chromatography (HPLC).

Main Results:

  • Isoniazid release was significantly higher from the polyethylene glycol (PEG) base compared to lipophilic bases.
  • PEG suppositories released 70 ± 1.4 mg/mL of isoniazid.
  • Cocoa butter and Witepsol H15 released 55 ± 1.1 mg/mL and 18 ± 0.36 mg/mL, respectively.

Conclusions:

  • Water-soluble polyethylene glycol bases are superior for formulating isoniazid suppositories in children.
  • Optimized PEG-based suppositories offer a viable alternative route for isoniazid administration in pediatric TB.
  • Further research can refine these formulations for improved pediatric TB management.